Cellistic Announces Successful CRISPR intellectual property Asset Purchase
Cellistic now offers partners a proprietary Cas-12 gene editing technology, with full freedom to operate, enabling custom edits to cell therapy candidates with higher precision than conventional CRISPR technologies.
- Cellistic now offers partners a proprietary Cas-12 gene editing technology, with full freedom to operate, enabling custom edits to cell therapy candidates with higher precision than conventional CRISPR technologies.
- Pulse and Echo provide the optimal solution to accelerate the development of more consistent and cost-effective off-the-shelf allogeneic cell therapies.
- Cellistic specializes in process development and manufacture of immune cell therapies based on human induced pluripotent stem cell (iPSC) technology using their Pulse and Echo Platform.
- Interested in learning more about Cellistic and our new STAR-CRISPR technology, please reach out to our BD team.